

[News & Resources](#) > [News and Insights](#) > **Article**

CHAPERONE THERAPEUTICS AND ALS THERAPY DEVELOPMENT INSTITUTE ENTER INTO RESEARCH PARTNERSHIP

August 10, 2015

[Share](#)

CAMBRIDGE, MA & RESEARCH TRIANGLE PARK, NC – The [ALS Therapy Development Institute](#) and [Chaperone Therapeutics, Inc.](#), announced today that they have entered into a research partnership to explore potential treatments for [amyotrophic lateral sclerosis](#) (ALS). Chaperone has developed several promising small molecules targeting the activation of HSF1, a key modulator of pathways involved in protein folding and neuronal stress protection. The objective of the partnership is to complete preclinical optimization of lead candidates and develop a clinical development plan in ALS.



“Like many neurodegenerative disease indications, ALS appears to be a protein misfolding disorder,” said Steve Perrin, Ph.D., CEO and CSO of the ALS Therapy Development Institute. “The accumulation of these errant proteins results in cellular stress in motor neurons, loss of innervation of skeletal muscle, and paralysis in ALS patients. We are excited about the partnership with Chaperone. These lead molecules could be first in class treatments for neurodegenerative diseases such as ALS.”

Preclinical experiments with Chaperone Therapeutics’ small molecules are taking place at the ALS Therapy Development Institute’s facility in Cambridge, Massachusetts. The partners have designed cell-based assays to test the potential treatment’s ability to correct protein misfolding, protect neurons from stress-induced cell death as well as in vivo studies to assess the treatment’s effect on the progression of ALS.





Therapeutics. “We are delighted to work closely with the outstanding team at the ALS Therapy Development Institute to test our molecules that increase protein chaperone activity, as a potential disease modifying therapy for ALS.”

The research partners are working collaboratively to determine the potential application of Chaperone’s technology in ALS and will provide more information as it becomes available or published through a peer-reviewed journal.

The ALS Therapy Development Institute and Chaperone Therapeutics will hold a webinar about the research partnership on **September 22nd at 2:00 PM ET**. To register, please visit <https://www.alstdi.org/als-events/als-webinars/register/?id=09222015>.

About the ALS Therapy Development Institute

The ALS Therapy Development Institute and its scientists actively discover and develop treatments for ALS. The Institute is the world’s first and largest nonprofit biotech focused 100 percent on ALS research. Led by ALS patients and their families, the charity understands the urgent need to slow and stop this horrible disease. Based in Cambridge, MA, the Institute has served as one of the leaders in sharing data and information with academic and ALS research organizations, patients and their families. For more information, visit www.alstdi.org.

About Chaperone Therapeutics, Inc.

Chaperone Therapeutics is developing frontline therapies to address protein misfolding and neuronal cell loss, the underlying causes of neurodegenerative disease. Chaperone’s therapeutic approaches elevate the natural cellular protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing neuronal cell death. Chaperone’s unique drug discovery platforms, broad knowledge in small molecule optimization and expertise in animal models of neurodegenerative disease and clinical evaluation propel our therapeutic discovery programs forward. For more information, visit www.chaperonetherapeutics.com.





Author: [Mari Cody](#)

TALK WITH US

Whether you have questions about research, resources, clinical trials, or just want to connect and have a conversation, **we want to hear from you.**

Let us help →

FOLLOW US

Learn more about our team, what we're working on in the lab, and our amazing community by following us on social media!



RELATED READING

Hoops4ALS Wraps a Slam Dunk Season with Community and Creative Fundraising

Read more →

Anthony Carbajal on Why the ALS Ice Bucket Challenge Still Matters in 2025

Read more →

Highlighting the Many Kinds of ALS for ALS Awareness Month

Read more →



SUBSCRIBE

Sign up to receive updates about the latest ALS research, ALS TDI's work, and the community

Stay Informed

ALS is not an incurable disease. It is an underfunded one.

You make our critical ALS research possible. Support our mission to end ALS today.

DONATE TO ALS RESEARCH

Receive email updates about the latest ALS research and the community.

Subscribe

Contact Us

617.441.7200

info@als.net

Follow Us



Our Research

ALS Research Collaborative

Our Labs

Publications

AQ Translational Research Center

Take Action

Donate

Attend an Event

Browse Fundraisers

Get Updates

News & Resources

ALS Trial Navigator

News & Insights

ALS Town Hall



[Our Team](#)

[ALS TDI FAQ](#)

[Our Financials](#)

[Contact Us](#)

[Schedule a Lab Tour](#)

[ALS TDI Brand Tools](#)

What is ALS

[ALS Treatments](#)

[Newly Diagnosed](#)

[ALS FAQ](#)

[Glossary](#)

[Donate](#)

©2025 ALS TDI

480 Arsenal Street, Suite 201

Watertown, MA 02472

[Privacy Policy](#) • [Terms of Service](#) • [Cookie Declaration](#) • [Solicitation Disclosure Statements](#)

The ALS Therapy Development Institute is a registered 501(c)3 nonprofit. EIN # 04-3462719

